ASGCT 2026: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play
- 8 hours ago
- 1 min read
He describes the work he is involved in with ARTAN Bio, which has a tRNA suppressors approach to diseases of aging and logevity. Plus, a unique crypto financing angle to this story.
Coverage brought to you by










.png)
